Ono Pharma partners with Mediar Therapeutics on antibody drugs for fibro-inflammatory diseases

PUBT · 2d ago
Ono Pharma partners with Mediar Therapeutics on antibody drugs for fibro-inflammatory diseases
  • ONO Pharmaceutical entered a drug discovery partnership with Mediar Therapeutics to develop novel antibody therapies for fibro-inflammatory diseases.
  • Mediar will run discovery research using its fibrosis biology platform, targeting immune-mediated mechanisms linked to autoimmune pathology.
  • Ono secured an exclusive worldwide option to develop, manufacture, and commercialize antibody candidates generated under the collaboration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.